Peptidoglycan binding by a pocket on the accessory NTF2-domain of Pgp2 directs helical cell shape of Campylobacter jejuni

Chang Sheng-Huei Lin 1, Anson C. K. Chan 1, Jenny Vermeulen 2, Jacob Brockerman 3, Arvind S. Soni 1, Martin E. Tanner 1, Erin C. Gaynor 1, Lawrence P. McIntosh 4, Jean-Pierre Simorre 5, and Michael E. P. Murphy 1,6

1Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada; 2Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada; 3Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada; 4University of Grenoble Alpes, CNRS, CEA, IBIS, Grenoble, France

Edited by Wolfgang Peti

The helical morphology of Campylobacter jejuni, a bacterium involved in host gut colonization and pathogenesis in humans, is determined by the structure of the peptidoglycan (PG) layer. This structure is dictated by trimming of peptide stems by the LD-carboxypeptidase Pgp2 within the periplasm. The interaction interface between Pgp2 and PG to select sites for peptide trimming is unknown. We determined a 1.6 Å resolution crystal structure of Pgp2, which contains a conserved LD-carboxypeptidase domain and a previously uncharacterized domain with an NTF2-like fold (NTF2). We identified a pocket in the NTF2 domain formed by conserved residues and located ∼40 Å from the LD-carboxypeptidase active site. Expression of pgp2 in trans with substitutions of charged (Lys257, Lys307, Glu324) and hydrophobic residues (Phe242 and Tyr233) within the pocket did not restore helical morphology to a pgp2 deletion strain. Muropeptide analysis indicated a decrease of murotripeptides in the deletion strain expressing these mutants, suggesting reduced Pgp2 catalytic activity. Pgp2 but not the K307A mutant was pulled down by C. jejuni Δpgp2 PG sacculi, supporting a role for the pocket in PG binding. NMR spectroscopy was used to define the interaction interfaces of Pgp2 with several PG fragments, which bound to the active site within the LD-carboxypeptidase domain and the pocket of the NTF2 domain. We propose a model for Pgp2 binding to PG strands involving both the LD-carboxypeptidase domain and the accessory NTF2 domain to induce a helical cell shape.

* For correspondence: Michael E. P. Murphy, michael.murphy@ubc.ca.
profile to that of the Δpgp2 strain (7). Homologs of Pgp1 and Pgp2 are characterized in Helicobacter pylori, and both are required for maintaining helical cell shape (14, 15). The H. pylori homolog of Pgp2 is named Csd6 and shares 36% amino acid sequence identity.

Sequence analysis of Pgp2 indicates that it contains an LD-carboxypeptidase (LD-CPase) domain and an NTF2-like superfAMILY (NTF2) domain. NTF2 domains are broadly found in nature and function in both ligand binding and catalysis, including in other PG hydrolases such as PBP2a and NlpC/p60 (16, 17). Csd6 is suggested to be required for flagellin biosynthesis in H. pylori (18), and its NTF2 domain is proposed to bind a pseudaminic acid (19).

Here, we investigated the role of the NTF2 domain in maintaining C. jejuni helical shape. We report the crystal structure of Pgp2 and identified a conserved binding pocket in the NTF2 domain. Site-directed mutagenesis combined with interaction studies using PG fragments was used to show that the NTF2 domain binds PG and is required for C. jejuni helical shape. On the basis of these results, we propose a model for Pgp2-PG interaction involving both the LD-CPase and the NTF2 domains to guide catalytic activity.

**Results**

Two clusters of conserved residues are identified in the Pgp2 structure

A recombinant Pgp2 construct (Pgp243-325) containing residues 43–325 of the native sequence (cj81176.0915) is enzymatically active (20) and was suitable for structural characterization. Pgp2 crystallized in space group P2₁2₁2₁ and the structure was solved to 1.6 Å resolution by molecular replacement using Csd6 as a search model (PDB ID: 4XZZ). X-ray data collection and refinement statistics are summarized in Table S1. The Pgp2 structure contains one Pgp2 molecule in the asymmetric unit (Fig. 1A). Analysis in solution by dynamic light scattering indicated an average molecular weight of 44 kDa, consistent with the predicted weight of the recombinant Pgp2 monomer (36 kDa; not shown).

The structure of Pgp2 contains an N-terminal helix (residues Q43-I51), the catalytic LD-CPase domain (residues V65-K201), and the C-terminal NTF2 domain (residues K208-Q325), each connected to the next domain by a single loop (Fig. 1A). An extensive interface with a buried surface area of 1130 Å² is found between the LD-CPase and NTF2 domains,
as calculated by the PISA server (21). The LD-CPase domain consists of parallel strands \( \beta_5-\beta_6 \) sandwiched by a beta sheet (\( \beta_1-\beta_4 \) and \( \beta_7 \)), four helices (\( \alpha_2-\alpha_5 \)), and connecting loops. The likely catalytic triad (C174-H157-G158) is located on the central stands \( \beta_5-\beta_6 \) (Fig. 1, A and D). The NTF2 domain contains three helices (\( \alpha_6-\alpha_8 \)) wrapped around a curved antiparallel \( \beta \)-sheet (\( \beta_8-\beta_{11} \)), which together forms a cone shape domain with a broad protein.

Using a Dali search (22) for similar structures in the PDB, only Csd6 can be superimposed with Pgp2 over both the LD-CPase and NTF2 domains (PDB ID: 4XZZ, RMSD of 1.8 Å for 281 Ca atoms). The structure of Csd6 includes two additional \( \alpha \)-helices at the N terminus that forms a homodimerization domain between two Csd6 monomers. The equivalent 27 residues are absent in the truncated Pgp2 construct. The structure of Csd6 deviates from strands \( \beta_9-\beta_{10} \) of the Pgp2 NTF2 domain (Fig. 1B). The LD-CPase domain of Pgp2 is distantly related to LD- transpeptidases with sequence identity <20%. An example is LdtMt5 from *Mycobacterium tuberculosis* (PDB ID: 4Z7A, RMSD of 2.4 Å over 106 Ca atoms). The NTF2 domain is structurally similar to proteins with diverse functions, such as calmodulin-dependent protein kinase II from *Rattus norvegicus* (PDB ID: 5U6Y, RMSD of 2.4 Å over 109 Ca atoms) and penicillin-binding protein 2A, a Dd-transpeptidase from meticillin-resistant *Staphylococcus aureus* (PDB ID: 3ZFZ, RMSD of 2.7 Å over 95 Ca atoms).

To predict functionally important residues in Pgp2, 150 homologous sequences with 35%–95% sequence identity to Pgp2 were identified and aligned in ConSurf (23). The level of sequence conservation was mapped onto the surface of Pgp2 (Fig. 1C). Regions of high sequence conservation are observed on one side of the molecule, focused in two clusters. The first cluster is in proximity to the catalytic triad in the LD-CPase domain (Fig. 1D). The second cluster is formed by 17 primarily aromatic (41%) and charged (30%) residues that are clustered in the pocket of the NTF2 domain (Fig. 1D).

The LD-CPase and NTF2 domains are required for helical shape

Previously, integration of wild-type *pgp2* with its native promoter at a remote site of the \( \Delta \text{pgp2} \) chromosome restored normal cell shape in the straight-rod deletion strain (7). Using this supplementation system, we evaluated the importance of the two conserved clusters by constructing single residue Pgp2 variants. Mutants of *pgp2* encoding substitutions of catalytic residues (H157 and C174) or residues in the NTF2 pocket (Y233, F242, K257, K307, and E324) were generated, and the morphologies of these strains were examined by differential interference contrast microscopy. The \( \Delta \text{pgp2} \) strains complemented by mutants of the catalytic triad (H157A, C174S) displayed rod morphologies, confirming that Pgp2 catalytic activity is required for helical shape (Fig. 2A). Point mutations within the NTF2 pocket resulted in bacteria with partially curved to straight morphologies. Quantitative analysis of each strain by Celltool (24) indicated that strains complementation with native *pgp2* displayed a cell curvature distribution similar to wild-type cells, whereas the strains expressing Pgp2 mutants had similar lengths but varied in cell curvature (Fig. 2B). The catalytic triad mutants (C174S, H157A) and three mutants within the NTF2 pocket (Y233A, K257A, and K307A) resulted in bacteria with cell curvature distributions that were similar to the \( \Delta \text{pgp2} \) strain. Two mutants were of an intermediate phenotype (F242A and E324Q). These curvature defects were not due to Pgp2 expression deficiency as confirmed by Western blot using an anti-Pgp2 antibody (Figs. 2C and S1). Together, we concluded that the LD-CPase and NTF2 domains are both required for helical shape in *C. jejuni*.

Pgp2 was reported to be post-translationally modified (25). In this earlier study, Pgp2 purified from cell lysate using a carbohydrate-binding column displayed three spots by two-dimensional electrophoresis. Four \( N \)-linked glycosylation sequons (Asn-Xaa-Ser/Thr) were found in the sequence of Pgp2 suggesting that post-translational glycosylation likely gave rise to the two bands observed on the Western blot (Fig. 2C). No positive correlation was found from a quantification of the intensities of the two bands and a comparison against control.

The NTF2 domain is required for Pgp2 catalytic activity in *C. jejuni*

Pgp2 activity was quantified by assaying for the products (tryptophan or cross-linked tetrapeptides) in the hydrolyzed PG of *C. jejuni*. Purified PG from *C. jejuni* strains complemented with *pgp2* harboring point mutations was digested by muramidase and analyzed by high performance liquid chromatography (HPLC). The identities of peaks from the HPLC elution profile were confirmed by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Complementation with a catalytically inactive variant (C174S) produced undetectable levels of monomeric and cross-linked tripeptides (Fig. 3, left panel), and this variant served as a negative control. Lower levels of products were observed in the NTF2 domain mutant strains (K257A, K307A, and E324Q) relative to the strain expressing wild-type Pgp2 (Fig. 3, left panel). The proportion of monomeric tripeptides ranged from 14% to 25%, whereas the proportion of cross-linked tetrapeptides ranged from 41% to 95% (Fig. 3, right panel), demonstrating that the NTF2 domain is required for full Pgp2 activity in *C. jejuni*. Furthermore, for NTF2 mutants, the activity on monomeric tetrapeptides was diminished more than for cross-linked tetrapeptides.

The NTF2 domain binds PG

In some multidomain PG hydrolases, the presence of a PG-binding domain enhances the activity of the catalytic domain (26, 27). We examined whether the NTF2 domain functions as a PG-binding domain that is synergistic with the LD-CPase domain for Pgp2 catalytic activity. A pull-down experiment was performed with Pgp2 \( ^{\text{C365}} \) and variants using \( \Delta \text{pgp2} \) PG, which is rich in tetrapeptides. Wild-type Pgp2 was pulled down, demonstrating PG binding (Fig. S2A). Two catalytically inactive variants, C174S (Pgp2 \( ^{\text{C174S}} \)) and H157A (Pgp2 \( ^{\text{H157A}} \)),...
showed minimal association. The K307A variant (Pgp2^K307A), a conserved residue within the pocket of the NTF2 domain, was also weakly associated, supporting a role for this binding pocket for appreciable PG interaction. Mutation of conserved Y233 in the NTF2 domain (Pgp2^Y233F) was insufficient to disrupt the pull down of Pgp2 by PG. The removal of one hydroxyl group by replacement of tyrosine by phenylalanine was insufficient to substantively decrease PG binding.

Strands β9–β10 form a flexible lip of the NTF2 domain binding pocket

To investigate if the loss of PG binding by the Pgp2^K307A was due to conformational change, the crystal structure of this variant was solved at 1.85 Å resolution (Table S1). The Pgp2^K307A crystal structure contains two Pgp2^K307A molecules in one asymmetric unit that superimposed with an RMSD of 0.7 Å over 281 Cα atoms. The fold of the Pgp2^K307A is similar to that of wild-type Pgp2 (RMSD of 1.5 Å over 277 aligned Cα atoms). The largest deviation is located at residues 296–306 of strands β9–β10 (Fig. S3, A–C), which form a protruding lower lip of the NTF2 domain binding pocket. An overlay of the structures of Pgp2, Pgp2^K307A, and H. pylori Csd6 (PDB ID: 4XZZ) showed that the conformation of lower lip is more similar between the latter two (Fig. S3, A–D). In the wild-type Pgp2 crystal structure, the average B-factor of β9–β10 (residues 292–310) was 53.4 Å², 1.8-fold higher than the average B-factor over all residues. We conclude that β9–β10 is conformationally flexible and may allow variation in ligand specificity.

Identifying PG-binding interfaces of Pgp2 by NMR-monitored titrations

To identify PG interaction sites by NMR spectroscopy, triple-labeled (^2H, ^13C, ^15N) Pgp2^43–325 was produced and used
to obtain the assignments of 236 out of 287 expected main chain amide $^{1}H_{N}^{15}N$ signals (Fig. S4A). The unassigned residues include those in two loops (residues 167–173 and 238–253) for which conformational exchange may have led to resonance broadening. Although deuteration was required for resonance assignments of this 36 kDa protein, the $^{15}N$-BEST-TROSY-HSQC spectrum of $^{15}N$-labeled Pgp2$^{243-325}$ was of high quality (Fig. S4B), enabling titration experiments with panels of PG-derived ligands.

Four PG ligand preparations for titration experiments were derived from digesting whole PG: a muramidase digestion of C. jejuni Δpgp2 PG, a DL-endopeptidase (Pseudomonas aeruginosa Tse1) digestion of Escherichia coli PG, HPLC-purified murotetrypeptide, and HPLC-purified cross-linked murotetrapeptides. The latter two ligands were treated with sodium borohydride before purification, which reduced the MurNAc residue. A fifth ligand was a synthesized peptide analogue (D-Glu-m-oxa-Dap-D-Ala) of the Pgp2 substrate (20).

In general, the $^{1}H$ and $^{15}N$ chemical shifts of many amides in Pgp2 changed progressively with added ligand (Fig. 4). This corresponds to the fast exchange regime on the chemical shift timescale ($k_{ex} >> \Delta \omega$, where $k_{ex}$ is the interconversion rate constant and $\Delta \omega$ is the chemical shift difference between free and bound states) and is indicative of relatively weak binding (28). Such a response enabled their signals to be followed over the course of the titration, and their chemical shift perturbations (CSPs) to be calculated as the square root of the sum of the squared $^{1}H$ and $^{15}N$ chemical shift differences between the apo- versus ligand-bound protein at the titration end point (29). To define residues most perturbed by ligand binding, a CSP cut-off was determined for each given titration based on the average CSP value for all residues, combined with patterns of clustering when mapped to the structure. In some cases, increasing linewidths and decreasing intensities of amide signals also occurred upon ligand binding (Fig. S5). This typically corresponds to the intermediate exchange regime ($k_{ex} \sim \Delta \omega$) and could arise from larger amide chemical shift changes upon binding, or perhaps sensitivity to exchange between multiple bound conformations. Although precluding the measurement of CSP values, the patterns of such spectral perturbations aided in the identification of ligand-binding sites.

Titrations with D-Glu-m-oxa-Dap-D-Ala identified three patches of amides in the protein with CSP values above the cut-off (Figs. 5 and 6A). These include a patch next to helix α2 and strand β5 of the active site in the LD-CPase domain (Y130, W155, H157, and Y159), consistent with slow hydrolysis of the synthetic substrate by Pgp2 (20). The second patch is located on the pocket of the NTF2 domain at helix α8 and strands β8–β10 (S262, E265, K268, F271, D273, N275, I276, Y296-T298, Q302, R304, and D306). A cluster of residues along helix α8 and strand β9 also showed signal broadening during the titrations (M256, I260, D266, K267, F292). This confirms the role of the NTF2 domain in PG binding. The third small patch is primarily from a loop with low sequence conservation at the inter-domain interface (N281, L282, and N284-M287) along the surface on the opposite side of both the LD-CPase domain active site and the NTF2 domain pocket.

Titrations using purified murotetrapeptide resulted in amides with line broadening or CSPs above the cut-off localized to three main patches (Figs. 5 and 6B). One patch, which includes helix α2, strand β5, and nearby loops (F123, Y130, F133–F135, T137, G152, G153, W155, H157, Y159, L166, C174, and L177), corresponds to a more extended interface near the Pgp2 active site than seen with the synthetic peptide. The second patch lies on the NTF2 pocket with residues within helices α7–α8 and strands β9–β11 showing extensive line broadening. The third backside patch is located at loops between the two domains (N281-L282 and N284-T286, E202-I204, D314-K316, K318) and is more extended than seen with the peptide titration. Titrations of purified cross-linked murotetrapeptides identified the same three patches (Figs. 5 and 6C). No significant differences in the patterns of amide spectral perturbations were observed between monomeric murotetrapeptide and cross-linked murotetrapeptides. This suggests that, even when cross-linked, the murotetrapeptides (and the synthetic peptide) bind to distinct interaction surfaces on Pgp2.

A titration with muramidase-digested Δpgp2 PG identified a predominant patch within the NTF2 pocket that includes residues A224, W225, K268, I269, Y297, and K307, which are located along helix α6 and strands β8–β10 within the NTF2 pocket (Figs. 4, 5, and 6D). Considerable resonance broadening.
was also observed for the nearby residues, including Y233 and Y237 of helix α7, A254 and M256-S262 of helix α8, E265-K267, and residues of strands β9–β11. An analysis of peak intensity changes over the course of the titration revealed the largest reductions for amides on strands β8–β10 of the NTF2 domain (I269-F271, D273, F292, Y297, K299, Y301, and K307) (Fig. S5). Thus, under the conditions of this titration experiment, the digested PG mixture primarily bound to the NTF2 pocket.

Titration with Tse1-digested E. coli PG showed patterns of small CSPs for amides located at helices α6 and α8 (T220, W225, R263, and K264) and strands β8–β10 (F271, D273, I276, L282-N284, S291-F292, Y301, G305, K307, and L309) along the NTF2 domain pocket (Figs. 5 and 6E). In addition, resonance broadening was associated with residues on helices α6–α8 and strands β9–β11. Thus, Tse1-digested E. coli PG also bound to the pocket of the NTF2 domain, with little measurable association near the active site of the LD-CPase domain. This may reflect a relatively low endpoint concentration of the PG used for the titration and a decrease in tetrapeptides due to the cleavage mechanism of Tse1 (30). As perturbations of resonances of residues in the NTF2 pocket were observed by NMR when titrating with PG fragments, including residues that when mutated gave rise to a straight phenotype (Y233, K257, K307), binding of PG by the NTF2 domain may be a necessary for C. jejuni helical shape generation.

**NMR data-driven docking to identify binding modes between Pgp2 and PG**

NMR-monitored titrations identified three major PG-binding sites: the catalytic cleft, the NTF2 pocket, and a backside patch. The titration with purified murotetrapeptide exhibited the largest continuous patch of perturbed residues in the catalytic cleft and the backside patch, and the muramidase-digested PG mixture displayed extensive perturbations in the NTF2 pocket. These two NMR titration data sets were therefore chosen for computational docking experiments using HADDOCK (31, 32) to construct a model of the Pgp2-PG complex. To overcome the inherent challenges of identifying bound conformations of a flexible ligand in molecular docking, an ensemble of murotetrapeptide conformers was derived by sampling molecular dynamic simulations using CNS. In addition, we used two Pgp2 crystal structures (WT and Pgp2K307A) as initial docking conformers.

For the docking using CSP data from the murotetrapeptide titration experiment, an unambiguous distance restraint of 2.0 Å between the nucleophile (Cys174) and the carbonyl carbon of m-DAP was added. The top 200 docking solutions were grouped into five clusters with a coverage rate of 92.5%
The largest cluster (88 solutions) had the best HADDOCK score with reasonable distances between nucleophilic C174 and the carbonyl carbon of \( \text{m-DAP} \) (Fig. 7A). Contacts within the complex were primarily between the active cleft and peptide moiety, with minor interactions between the protein and sugar moiety. Within this cluster, all disaccharides point away from the active cleft. The second major cluster (68 solutions) features contacts primarily between the murotetrapeptide and loops of the domain interface on the backside of Pgp2 (Fig. 7A). The solutions in this cluster are catalytically unfavorable because the nucleophilic attack distance for C174 is over 18 Å.

For docking using the CSP data from the titration with muramidase-digested PG, no unambiguous distance restraints...
were included. The top 200 solutions were grouped into five clusters with a coverage rate of 95.5% (191/200) (Table S2). The largest cluster (126 solutions) had the best HADDOCK score, featuring strands $\beta_8$–$\beta_{12}$ and helix $\alpha_8$ of the NTF2 domain pocket interacting with the peptide moiety (Fig. 7B). The contact regions within the second cluster (31 solutions) are similar to cluster 1 but position the backbone sugar in the reverse direction. The remaining clusters had poor scores with small buried surface areas.

Selecting the best solutions from the docking of a murotetrapeptide to the catalytic and NTF2 domains (Fig. 7C), we generated a model of Pgp2 bound to PG by manually building a bridging PG polymer between the two docked muropeptides, which are $\sim$40 Å apart (Fig. 8A). This PG strand runs the length of the Pgp2 molecule. Csd6 is a dimer formed by a small dimerization domain at the N terminus. Much of this domain is absent in the recombinant Pgp2 construct used in these biochemical studies. Based on homology to Csd6, full-length...
Pgp2 is expected to also form a dimer. To model PG binding to the Pgp2 dimer, two Pgp2-PG complexes were superimposed onto crystal structure of the Csd6 dimer (PDB ID: 4XZZ) (Fig. 8). Remarkably, the two PG strands are on one face of the dimer and run antiparallel 32 Å apart, close to the interstand distance of model cross-linked PG (33).

**Discussion**

Pgp2 is annotated to be within the YkuD protein family (PF03734) (34), which are LD-transpeptidases (LD-TPase) with a conserved catalytic triad of Cys, His, and the main-chain carbonyl of a third residue (Gly in Pgp2) (35). LD-TPases bind two muropeptide stems in the active cleft to catalyze the formation of (L) m-Dap^{n}→(D) m-Dap^{3} cross-links (36). However, the catalytic cleft of Pgp2 can only accommodate a single muropeptide and a water molecule for peptide bond hydrolysis. Superimposition of the LD-CPase domain of Pgp2 and the LD-TPase domain of LdtMt5 from *M. tuberculosis* (PDB ID: 4Z7A) revealed that the Pgp2 loops composed of residues 102–115 and 138–151 block the entry of an acyl receptor, consistent with the absence of 3–3 cross-links in *C. jejuni* PG (6).

The catalytic domain of Pgp2 shares conserved features with Csd6, the LD-CPase from *H. pylori* (Fig. S3E). The arrangement of the catalytic triad (C174, H157, and G158) is conserved. Also conserved are residues (E107, Y130, and W155, Pgp2 numbering) interacting with two bound D-Ala molecules observed in the Csd6 active site (19). One D-Ala is proposed to mimic the binding of the D-Ala residue of the peptide stem substrate, whereas the second D-Ala is thought to bind in the m-DAP subsite. Despite these similarities, Pgp2 cleaved both monomeric and cross-linked tetrapeptides in a biochemical assay with recombinant enzyme containing the predicted dimerization domain (residues 19–325) and purified *C. jejuni* PG (7), whereas the equivalent Csd6 construct (residues 18–303) fully cleaved monomeric tetrapeptides with only trace digestion of cross-linked tetrapeptides in purified *H. pylori* PG (15). We assayed the same purified *H. pylori* Csd6 construct with *C. jejuni* PG and observed digestion of both monomeric and cross-linked tetrapeptides (Fig. S2B). Taken together, the difference in activity may thus be due to the differing PG architectures as opposed to enzyme substrate specificity differences.
Peptidoglycan recognition by Pgp2 directs cell shape

Our pull-down data demonstrate that both the LD-CPase and NTF2 domains of Pgp2 are required for high-affinity binding to PG (Fig. S2A), a feature not previously observed for the LD-CPase enzyme family. Many cell wall enzymes contain a noncatalytic NTF2 domain in addition to their catalytic module. For example, an NTF2 domain is found in a subset of class B penicillin-binding proteins (16, 37), the DD-endopeptidase NlpD, and β-lactamase (17). These NTF2 domains may also be required for high-affinity PG binding, playing a role in the recognition of specific local PG structural features and guiding catalysis. Characterizing the structures and substrate preferences of the NTF2 domain from these enzymes will determine how this domain is adapted to diverse roles in PG metabolism.

We observed extensive NMR spectral perturbations clustered into three regions on the surface of Pgp2 upon titration with model PG ligands (i.e., the CPase active site, the NTF2 pocket, and a third backside patch; Fig. 6, A–C). The conserved CPase active site and NTF2 domain pocket are ~40 Å apart along the same side of the protein surface. The glycan backbone of PG was proposed to preferentially form a right-handed helix with a periodicity of 30–40 Å, or approximately three to four GlcNAc-MurNAc repeats with successive peptide stems projecting outward from the glycan strand screw axis (38, 39). As the top solutions from NMR-data driven docking at both domains position two bound murotetrapeptides oriented such that they can originate from a single right-handed PG strand (Fig. 7C), we propose this as the most parsimonious Pgp2-PG binding model, an interaction that simultaneously involves both the catalytic and NTF2 cavities (Fig. 8A).

The backside patch features low sequence conservation and was prominent during titrations with the synthetic peptide analog and purified monomeric and cross-linked murotetrapeptides (Fig. 6, A–C). Situated between the two domains, the region may be involved in allosteric coupling of the two frontside binding sites. Neither the third patch nor the active site exhibited strong relative perturbations when titrated with enzymatically digested PG (Fig. 6, D and E). This may reflect low relative concentrations of each muropeptide in the PG mixture and complex binding dynamics arising from multiple binding sites.

Pgp2 likely forms a higher oligomerization state within the bacterial cell. The Pgp2 homolog Csd6 dimerizes through three N-terminal helices from each monomer, building a six-helix bundle (19). The hydrophobic dimer interface of Csd6 is composed of the sequence IMRLX₅GLEMV. The N-terminal residues, including the hydrophobic dimer interface (LVRIYX₅GLDAV), are conserved in Pgp2 but missing in the truncated recombinant construct. We used the crystal structure of the Csd6 dimer (PDB ID: 4XZZ) and our PG docking data to predict the interaction of a Pgp2 dimer with PG (Fig. 8B). In this model, the PG interaction interface of both Pgp2 monomers is on the same face of the dimer. The Pgp2 dimer can interact with two PG strands ~32 Å apart, allowing for recognition of an ordered PG tertiary structure that may direct patterned digestion of the PG to form helical shape.

Some Pgp2 and PG structural features were not included in the generation of the proposed model. Firstly, the docked murotetrapeptides did not include acetylation at O6 of MurNAc. Secondly, strands β9–β10, which form the lip of the NTF2 pocket, are flexible (Fig. S3, A–D), and this flexibility may alter binding specificity. Lastly, a more complex PG-binding model is possible in which the two muropeptides bound to the active site and NTF2 domains originate from separate glycan strands ~40 Å apart. In this alternate model the Pgp2 dimer could interact with up to four distinct PG strands. Solid-state NMR can be used to calculate the 13C-15N internuclear distance of D-[1-13C]Ala and L-[15N]Ala-labeled PG peptide stems (40) and may be able to resolve these possibilities. Attempts to cocrystallize Pgp2 with synthesized peptide D-Glu-m-oxa-Dap-D-Ala and purified murotetrapeptide were ultimately unsuccessful.

Bacterial cell shape requires the spatial coordination of PG insertion (41). A localized “shaposome” complex, coordinated across the cytoplasm, inner membrane, and periplasm, is proposed to contribute to helical shape generation in H. pylori via asymmetrical cell wall synthesis (42–44). However, no interactions were identified between Pgp2 and PG synthesis machinery. Biophysical modeling suggests that spatially targeted PG growth (45–47) or changes to the degree of cross-linking along a helical axis can lead to a helical cell shape (48, 49). Neither overall growth rates (7) nor cell length (Fig. 2B) was affected upon the deletion of Pgp2. However, Pgp2 may modulate spatial PG insertion or cross-linking. The percentage of cross-links are similar between the wild-type (47.9%) and Δpgp2 (47.6%) strains (7), suggesting that the overall proportion of cross-links is not sufficient to determine helical shape. Instead, the deletion of Pgp2 increases the ratio of tetra-tetra to tetra-tri cross-links due to the absence of tripeptides (7). In H. pylori, the overall proportion of cross-links is also unaffected upon the deletion or overexpression of Csd6, but the ratio of tetra-tetra to tetra-tri cross-linked peptide stems varies (15). Both deletion and overexpression of Csd6 give a straight cell shape, suggesting that helical shape requires a proper balance between these two types of cross-links.

We show that Pgp2 has higher enzymatic activity on monomeric as compared with cross-linked peptides (Fig. 3), consistent with previous experiments using synthetic model peptides and purified PG (7, 20). By mutating conserved NTF2 domain pocket residues, we demonstrate that this domain impacts enzyme activity and is required for the preference for monomeric substrates in C. jejuni. Point mutations in the NTF2 domain resulted in a 75–86% reduction in the proportion of monomeric tripeptide products in C. jejuni PG as compared with wild-type. The same mutations reduced cross-linked tetratripeptides by 5–59% in the same samples. Clearly, muropeptide distribution is insufficient to determine shape phenotype. The NTF2 domain mutants (K257A, K307A, E324Q) have a similar loss in monomeric and cross-linked tripeptides but differ in shape phenotype ranging from curved to straight rods (Fig. 2, A and B). Nonetheless, these mutants may differ in function, such as modified localization...
or targeting of PG substructures, which would lead to the shape phenotypes.

Based on the evidence that NTF2 domain binds to PG and regulates Pgp2 activity, we propose that preferential trimming of monomeric tetrapeptides by Pgp2 is localized to one of the helical axes. Since tripeptides produced by Pgp2 can be further digested to release m-DAP by the DL-carboxypeptidase Pgp1 (7), they are no longer able to form cross-links. Thus, Pgp2 activity along a helical axis may allow for local relaxation of the PG, leading to cell twist. Future examination of Pgp2 localization and involvement of the NTF2 domain will test this model.

The requirement of Pgp2 for helical shape may serve as a basis for antimicrobial development as *C. jejuni* colonization within the host could be reduced. This strategy was successfully employed to target Pgp1 and the *H. pylori* homolog Csd4 (50). Incubation of bacteria with a small-molecule inhibitor of the carboxypeptidase domain results in a morphological shift from helical to straight rod cells. Unlike the LD-CPase domain, which is found in both helical and nonhelical-shaped cells, the NTF2 domain appears to be restricted to helical-shaped cells, suggesting that the NTF2 domain may be a more selective target.

In summary, we show that helical shape in *C. jejuni* depends on both the LD-CPase and NTF2 domains of Pgp2. Our proposed Pgp2-PG model highlights the importance of PG binding by the NTF2 domain that may guide Pgp2 activity through recognition of PG architecture.

**Experimental procedures**

**Crystal structure determination**

The Pgp2 and Pgp2^K307A structures were determined by molecular replacement. The methods used for recombinant protein expression, crystallization, and structure determination are described in Text S1 (supporting information).

**Complementation with wild-type and site-directed mutagenesis variants Pgp2 in a Δppg2 strain**

Complementation of Δppg2 was achieved using a ppg2 complementation plasmid (7). The ppg2 gene and promoter were amplified from *C. jejuni* 81–176 genomic DNA and cloned into the pRRC vector (51). The inserted ppg2 gene included 196 bp of the native promoter region and 190 bp of the downstream sequence. The complementation plasmid was integrated into an available strain 81–176 Δppg2 mutant (7) by natural transformation. The transformed *C. jejuni* cells were grown at 38 °C under microaerophilic conditions (12% CO₂, 6% O₂, and N₂) in a trigas incubator. Colonies were selected on MH-TV media and grown for 4 h at 38 °C under microaerophilic conditions (Oxoid CampyGen) to log phase (OD₆₀₀ 0.1–0.3). Cells were mounted on a 1% agarose gel pad on a glass slide and imaged with a Nikon Eclipse TE2000-U microscope equipped with 100× oil-immersion objective and a Hamamatsu C4742-95 digital camera. Cell images were transformed into binary mode with GIMP software and analyzed with the Celltool software package (24).

**PCA analysis on wild-type cell contours of ~400 cells from each strain generated a shape mode that described cell curvature from straight to highly curved morphology. To compare the curvature distributions of each strain to the distribution of wild-type cells, all cells were aligned with the averaged morphology of wild-type cell by iterative translation and rotation.**

**Preparation of peptidoglycan and muropeptides**

*C. jejuni* was cultured on 100 MH-T plates for 18 h at 38 °C, and at late log phase cells were collected cold MH-TV media (1 ml/plate) by scraping. Culture medium was removed by centrifugation at 5000 rpm at 4 °C for 10 min and the cell pellet was resuspended in 80 ml cold PBS buffer. Cells were lysed by mixing with an equal volume of boiling 6% SDS for 4 h and centrifuged at room temperature to remove intact cells. The PG was pelleted from the cell lysate by ultracentrifugation at 45,000 rpm at 22 °C for 3 h and washed with water. To remove glycogen and lipoproteins, the PG was resuspended in buffer (10 mM Tris pH 7.0 and 150 mM NaCl) and digested sequentially with alpha-amylase (200 µg/ml) and Pronases (200 µg/ml) at 37 °C overnight. The PG sample was boiled in 6% SDS for 10 min followed by centrifugation (10,000 rpm, room temperature, 10 min). SDS was removed by three washes with water and ultracentrifugation (45,000 rpm at 22 °C for 3 h). PG samples were lyophilized in water and stored at −20 °C. To prepare muropeptides, 0.2 mg PG was digested with 50 U mutanolysin (Sigma) in 50 mM Tris pH 7.0 and 150 mM NaCl at 37 °C for 24 h. Mutanolysin was removed by boiling for 10 min and centrifugation. Muropeptides prepared for HPLC analysis were reduced with 100 mM sodium borohydride pH 9.0 at room temperature for 30 min, titrated to pH 4 with phosphoric acid, and passed through a 0.22 um filter.

**HPLC muropeptide analysis**

Muropeptide separation by HPLC was performed with an Xterra MS C18 column (Waters) and UV detection at 210 nm. Elution relied on a gradient from 100% buffer A (sodium phosphate buffer 50 mM pH 4.3) to 100% buffer B (sodium phosphate buffer 50 mM pH 4.9 and methanol 15% (v/v)) over 100 min.

**NMR titration experiments**

NMR titration experiments were performed with ¹⁵N-labeled Pgp2. The assignment of Pgp2 amide resonances was
Peptidoglycan recognition by Pgp2 directs cell shape

achieved with ²H⁻¹³ C⁻¹⁵N Pgp2 as described in the supplemental Text S1. PG ligand titration studies with ¹⁵N-labeled Pgp2 were monitored by ¹⁵N-BEST-TROSY-HSQC at 25 °C for different ligand-to-protein ratios. PG ligand was dialyzed against water using a float dialysis membrane device with a 100–500 Da cut-off (Spectrum Laboratories, Inc) and lyophilized before preparation of a concentrated stock solution in NMR buffer (52). A 160 μM sample of ¹⁵N-labeled Pgp2 was titrated with 3.4 and 6.8 μl of D-Glu-m-oxa-Dap-D-Ala (4 μg/μl; MW 434.2 g/mol), giving a final peptide:protein molar ratio of 2:1. A 160 μM sample of ¹⁵N-labeled Pgp2 was titrated with 5, 10, and 20 μl of purified murotetrypeptide (50 μg/μl; MW 941.1 g/mol) to a final peptidoprotein molar ratio of 33:1. A 160 μM sample of ¹⁵N-labeled Pgp2 was titrated with 5, 10, and 20 μl of purified cross-linked murotetrypeptides (50 μg/μl; MW 1864.8 g/mol) to a final peptidoprotein molar ratio of 16:1. A 160 μM sample of ¹⁵N-labeled Pgp2 was titrated with 5, 10, and 20 μl of muramidase-digested Δpgp2 PG solution (60 μg/μl) to a final concentration of 5.5 μg/μl. A 110 μM sample of ¹⁵N-labeled Pgp2 was titrated with 60 μl of Tse1-digested E. coli PG (~30 μg/μl) to a final concentration of ~4 μg/μl. Spectra were overlaid in NMRFAM-SPARKY, and CSP (Δδ) values were calculated as Δδ = \sqrt{(Δδ₁)² + (0.14 × Δδ₂)²}, where Δδ₁ and Δδ₂ denote the observed changes of the amide ¹⁵N and ¹³C chemical shifts in the absence versus presence of PG ligand at the final highest concentration used for a titration series.

Data-driven docking

Models of Pgp2 in complex with murotetrypeptides were produced in HADDOCK 2.2 (31). Two starting conformers for Pgp2, based on the wild-type and Pgp2K307A crystal structures, were generated as they differed in the NTF2 loop region that overhangs the pocket entrance. Unmodeled side chains were manually rebuilt and residue 307 was restored to Lys in Pgp2K307A using Coot (53) prior to docking. The sugar moieties coordinates and topology files of GlcNAc-GlcNAc with a β-1,4 glycosidic bond with a phi/psi angles of 69°/12° (38) were produced with the GlyCNS server (54). Tetrypeptide coordinates and topology files were generated with the PRODRG server (55) using a tetrapeptide model extracted from PDB entry 2MTZ. An ensemble of 20 murotetrypeptide conformers were generated by simulated annealing and energy minimization (56).

Ambiguous Interaction Restraints (AIRs) are defined as either active residues involved in binding or passive residues potentially involved (Table S2). The active residues of Pgp2 were defined as solvent accessible residues with a CSP above a cut-off in the murotetrypeptide titration experiment and from the list of functional residues identified by mutagenesis. The passive residues of Pgp2 were defined as the proximal residues within 5 Å of the active residues. The active residues of the murotetrypeptide were the peptide moiety and the passive residues were the sugars. For the docking experiment using data from a titration with purified murotetrypeptide, an unambiguous distance constraint (2.0 Å) was defined between the sulfur of the nucleophile Cys174 and the carbonyl carbon of m-DAP. A sample of 10,000 docking solutions were generated at the rigid body stage. The top 400 complexes based on HADDOCK score were used subjected to simulated annealing and the resulting top 200 complexes were further refined with waters. The docking solutions formed five clusters using a fraction of common contacts (FCC) cut-off of 0.45. In a second docking experiment, the active residues of Pgp2 were defined from residues with CSP above the cut-off in the muramidase digested Δpgp2 PG titration experiment. Both the peptide and sugar moieties of the murotetrypeptide were defined as passive residues. The final 200 solutions were grouped into five clusters using the FCC cut-off of 0.4.

Data availability

The atomic coordinates and structure factors of Pgp2 and Pgp2K307A have been deposited in the Protein Data Bank under ID codes 6XJ6 and 6XJ7. Pgp2 chemical shift assignments have been deposited to the Biological Magnetic Resonance Data Bank under ID 50689.

Supporting information—This article contains supporting information (57–65).

Acknowledgments—We would like to thank Dr Mark Okon, Dr Cecilia Perez-Borrjero, and Karlton Scheu for their help with NMR data collection and analysis; lan Yen for protein sample preparation; and Dr Seemay Chou (UCSF) for providing the Tse1-expression construct. We also like to thank Dr Emilisa Fridrich and Dr Tomas Richardson-Sanchez for critically reviewing the article. Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (P41GM103393). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH. Research described in this paper was performed using Beamlines 08B1-1at the Canadian Light Source, a national research facility of the University of Saskatchewan, which is supported by the Canada Foundation for Innovation (CFI), the Natural Sciences and Engineering Research Council (NSERC), the Natural Research Council (NRC), the Canadian Institutes of Health Research (CIHR), the Government of Saskatchewan, and the University of Saskatchewan. Instrument support was provided by the Natural Sciences and Engineering Research Council (NSERC) of Canada and the University of British Columbia.

Author contributions—C. S. H. L., A. C. K. C., and M. E. P. M. designed the study and wrote the article. J. V. obtained the C. jejuni complementation strains. J. B. and J. P. S. collected the NMR spectra and assisted with resonance assignments. A. S. S. collected and analyzed murotetrypeptide mass spectra. C. S. H. L. performed all the other experiments, processed and analyzed the data. M. E. T., E. C. G., L. P. M., and J. P. S. discussed the results and commented on the article.
Genomic variations leading to alterations in cell morphology of Campylobacter spp. Sci. Rep. 6, 38303
14. Sycuro, L. K., Wyckoff, T. J., Biboy, J., Born, P., Pincus, Z., Vollmer, W., and Salama, N. R. (2012) Multiple peptidoglycan modification networks modulate Helicobacter pylori’s cell shape, motility, and colonization potential. PLoS Pathog. 8, e1002603
15. Sycuro, L. K., Rule, C. S., Petersen, T. W., Wyckoff, T. J., Sessler, T., Nagarkar, D. B., Khalid, F., Pincus, Z., Biboy, J., Vollmer, W., and Salama, N. R. (2013) Flow cytometry-based enrichment for cell shape mutants identifies multiple genes that influence Helicobacter pylori morphology. Mol. Microbiol. 90, 869–883
16. Lim, D., and Strynadka, N. C. (2002) Structural basis for the beta lactam resistance of PBPs from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol. 9, 870–876
17. Eberhardt, R. Y., Chang, Y., Bateman, A., Murzin, A. G., Axelrod, H. L., Hwang, W. C., and Aravind, L. (2013) Filling out the structural map of the NTF2-like superfamly. BMC Bioinformatics 14, 327
18. Akasaka, H., Churin, Y., Bauer, B., Boettcher, J. P., Bartfeld, S., Hashi, N., Kawasaki, N., Mollenkopf, H. I., Jungblut, P. R., Brinkmann, V., and Meyer, T. F. (2010) Helicobacter pylori HP0518 affects flagellin glycosylation to alter bacterial motility. Mol. Microbiol. 78, 1130–1144
19. Kim, H. S., Im, H. N., An, D. R., Yoon, J. Y., Jang, J. Y., Mobashery, S., Hsek, D., Lee, M., Yoo, J., Cui, M., Choi, K., Kim, C., Lee, N. K., Kim, S., Kim, J. Y., et al. (2015) The cell shape-determining Csd6 protein from Helicobacter pylori constitutes a new family of L,D-Carboxypeptidase. J. Biol. Chem. 290, 25103–25117
20. Soni, A. S., Lin, C. S., Murphy, M. E. P., and Tanner, M. E. (2019) Peptidases containing meso-oxa-diaminopimelic acid as substrates for the cell-shape-determining proteases Csd6 and Pgp2. ChemBioChem 20, 1591–1598
21. Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797
22. Holm, L. (2020) DALI and the persistence of protein shape. Protein Sci. 29, 126–140
23. Ashkenazy, H., Erez, E., Martz, E., Pupko, T., and Ben-Tal, N. (2010) ConSurf 2010: Calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res. 38, W529–W533
24. Pincus, Z., and Theriot, J. A. (2007) Comparison of quantitative methods for cell-shape analysis. J. Microsc. 227, 140–156
25. Young, N. M., Brisson, J. R., Kelly, J., Watson, D. C., Tessier, L., Lanthier, P. H., Jarrell, H. C., Cadotte, N. St, Michael, F., Aberg, E., and Szymanski, C. M. (2002) Structure of the N-linked glycan present on multiple glycoproteins in the Gram-negative bacteria, Campylobacter jejuni. J. Biol. Chem. 277, 42530–42539
26. Rocabo, M., Herman, R., Sauvage, E., Remaut, H., Moonens, K., Terrak, M., Charlier, P., and Kerf, F. (2013) The crystal structure of the cell division amidase AmiC reveals the fold of the AMI domain, a new peptidoglycan binding domain. Mol. Microbiol. 90, 267–277
27. Mesnage, S., Dellarsole, M., Baxter, N. J., Rouget, J. B., Dimitrov, J. D., Wang, N., Fujimoto, Y., Hounslow, A. M., Lacroix-Dessazes, S., Fukase, K., Foster, S. J., and Williamson, M. P. (2014) Molecular basis for bacterial peptidoglycan recognition by LysMs domains. Nat. Commun. 5, 4269
28. Kleckner, I. R., and Foster, M. P. (2011) An introduction to NMR-based approaches for measuring protein dynamics. Biochim. Biophys. Acta 1814, 942–968
29. Williamson, M. P. (2013) Using chemical shift perturbation to characterise ligand binding. Prog. Nucl. Magn. Reson. Spectrosc. 73, 1–16
30. Chou, S., Bui, N. K., Russell, A. B., Lexa, K. W., Gardiner, T. E., LeRoux, M., Vollmer, W., and Mougous, J. D. (2012) Structure of a peptidoglycan amidase effector targeted to Gram-negative bacteria by the type VI secretion system. Cell Rep. 1, 656–664
31. Dominguez, C., Boelens, R., and Bonvin, A. M. (2003) Haddock: A protein-protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125, 1731–1737
32. van Zundert, G. C. P., Rodrigues, J., Trelet, M., Schmitz, C., Kastritis, P. L., Karaca, E., Melquiond, A. S. J., van Dijk, M., de Vries, S. J., and Bonvin, A. (2016) The HADDOCK2.2 web server: User-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 428, 720–725
Peptidoglycan recognition by Pgp2 directs cell shape

33. Dan, L., Chen, S., and Jensen, G. J. (2008) Molecular organization of Gram-negative peptidoglycan. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 18953–18957.

34. Bielicki, J., Devedjie, Y., Dereweda, U., Dauter, Z., Ioachimiaik, A., and Derewenda, Z. S. (2006) B. Subtilis ykD protein at 2.0 A resolution: Insights into the structure and function of a novel, ubiquitous family of bacterial enzymes. *Proteins* **62**, 144–151.

35. Lecou, L., Bougault, C., Hugonnet, J. E., Veckerle, C., Pessey, O., Arthur, M., and Simorre, J. P. (2012) Dynamics induced by beta-lactam antibiotics in the active site of Bacillus subtilis L,D-transpeptidase. *Structure* **20**, 850–861.

36. Maget, S., Arbeloa, A., Maimardi, J. L., Hugonnet, J. E., Forgueaud, M., Dubost, L., Marie, A., Delfosse, V., Mayer, C., Rice, L. B., and Arthur, M. (2007) Specificity of L,D-transpeptidases from gram-positive bacteria producing different peptidoglycan chemotypes. *J. Biol. Chem.* **282**, 13151–13159.

37. Macheloif, P., Contreras-Martel, C., Job, V., Dideberg, O., and Dessen, A. (2006) Penicillin binding proteins: Key players in bacterial cell cycle and drug resistance processes. *EMBS Microbiol. Rev.* **30**, 673–691.

38. Meroueh, S. O., Bencze, K. Z., Hesek, D., Lee, M., Fisher, J. F., Stemmler, B., Kim, S. J., Chang, J., and Singh, M. (2015) Peptidoglycan architecture of *Escherichia coli*. *J. Biol. Chem.* **280**, 4409–4419.

39. Bielnicki, J., Devedjiev, Y., Derewenda, U., Dauter, Z., Joachimiak, A., and Derewenda, Z. S. (2006) The active site of Bacillus subtilis L,D-transpeptidase. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 4044–4409.

40. Gumbart, J. C., Beeby, M., Jensen, G. J., and Roux, B. (2014) Escherichia coli peptidoglycan structure and mechanics as predicted by atomic-scale simulations. *Proc. Comput. Biol.* **10**, e1003475.

41. Margolin, W. (2009) Sculpting the bacterial cell. *Curr. Biol.* **19**, R812–R822.

42. Blair, K. M., Mears, K. S., Taylor, J. A., Fero, J., Jones, L. A., Gafken, P. R., Whitney, J. C., and Salama, N. R. (2018) The Helicobacter pylori cell shape promoting protein Csd5 interacts with the cell wall, MurF, and the bacterial cytoskeleton. *Mol. Microbiol.* **110**, 114–127.

43. Yang, D. C., Blair, K. M., Taylor, J. A., Petersen, T. W., Sessler, T., Tull, C. M., Loverich, C. K., Collar, A. L., Wyckoff, T. J., Biboy, J., Vollmer, W., and Salama, N. R. (2019) A genome-wide Helicobacter pylori morphology and drug resistance processes. *Appl. Environ. Microbiol.* **71**, 4004–4013.

44. Maya-Martinez, R., Alexander, J. A. N., Otten, C. F., Ayala, I., Vollmer, D., Gray, J., Bougault, C. M., Burt, A., Laguri, C., Fonvielle, M., Arthur, M., Strynandka, N. C. J., Vollmer, W., and Simorre, J. P. (2018) Recognition of peptidoglycan fragments by the transpeptidase PB4 from Staphylococcus aureus. *Front. Microbiol.* **9**, 3223.

45. Emshley, P., Lohkamp, B., Scott, B. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 861–877.

46. Kim, S. J., Chang, J., and Singh, M. (2015) Peptidoglycan architecture of Gram-positive bacteria by solid-state NMR. *Biochim. Biophys. Acta* **1848**, 350–362.

47. Wolgemuth, C. W., Inclan, Y. F., Quan, J., Mukherjee, S., Oster, G., and Koehl, M. A. (2005) How to make a spiral bacterium. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 189–199.

48. Cabeen, M. T., Charbon, G., Vollmer, W., Born, P., Ausmees, N., Weibel, D. B., and Jacobs-Wagner, C. (2009) Bacterial cell curvature through mechanical control of cell growth. *EMBO J.* **28**, 1208–1219.

49. Bartlett, T. M., Bratton, B. P., Duvshani, A., Miguel, A., Sheng, Y., Martin, N. R., Nguyen, J. P., Persat, A., Desmarais, S. M., VanNieuwenhze, M. S., Huang, K. C., Zhu, J., Sheevisz, I. W., and Gitai, Z. (2017) A periplasmic polymer curves Vibrio cholerae and promotes pathogenesis. *Cell* **168**, 172–185.e115.

50. Huang, K. C., Mukhopadhyay, R., Wen, B., Gitai, Z., and Wingreen, N. S. (2008) Cell shape and cell-wall organization in Gram-negative bacteria. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 19282–19287.

51. Syucro, L. K., Pincus, Z., Gutierrez, K. D., Biboy, J., Stern, C. A., Vollmer, W., and Salama, N. R. (2010) Peptidoglycan crosslinking relaxation promotes Helicobacter pylori’s helical shape and stomach colonization. *Cell* **141**, 822–833.

52. Liu, Y., Friidrich, E., Taylor, J. A., Chan, A. C., Blair, K. M., Vermeulen, J., Ha, R., Murphy, M. E., Salama, N. R., Gaynor, E. C., and Tanner, M. E. (2016) A bacterial cell shape-determining inhibitor. *ACS Chem. Biol.* **11**, 981–991.

53. Karlshev, A. V., and Wren, B. W. (2005) Development and application of an insertional system for gene delivery in Campylobacter jejuni. *Appl. Environ. Microbiol.* **71**, 4004–4013.

54. Schanda, P., Triboulet, S., Laguri, C., Bougault, C. M., Ayala, I., Callon, M., Arthur, M., and Simorre, J. P. (2014) Atomic model of a cell-wall cross-linking enzyme in complex with an intact bacterial peptidoglycan. *J. Am. Chem. Soc.* **136**, 17852–17860.

55. Schumann, K. W., and van Aalten, D. M. (2004) Prodig: A tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 1355–1363.

56. Brünger, A. T. (2007) Version 1.2 of the crystallography and NMR system. *Nat. Protoc.* **2**, 2728–2733.

57. Cai, M., Huang, Y., Yang, R., Craigie, R., and Clore, G. M. (2016) A simple and robust protocol for high-yield expression of perdeuterated peptides in Escherichia coli grown in shaker flasks. *J. Biomol. NMR* **66**, 85–91.

58. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* **276**, 307–326.

59. Lieschener, D., Afonine, P. V., Baker, M. L., Bunkoczi, G., Chen, V. B., Croll, T. I., Hintze, B., Huang, L. W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J., et al. (2019) Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr. D Struct. Biol.* **75**, 861–877.

60. Lescop, E., Schanda, P., and Brutscher, B. (2007) A set of BEST triple-resonance experiments for time-optimized protein resonance assignment. *J. Magn. Reson.* **187**, 163–169.

61. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRpipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* **6**, 277–293.

62. Lee, W., Tonelli, M., and Markley, J. L. (2015) NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. *Bioinformatics* **31**, 1325–1327.

63. Bahrami, A., Assadi, A. H., Markley, J. L., and Eghbalnia, H. R. (2009) Probabilistic interaction network of evidence algorithm and its application to complete labeling of peak lists from protein NMR spectroscopy. *PLoS Comput. Biol.* **5**, e1000307.